As part of its ongoing commitment to provide quality healthcare for Egyptians and accelerating solutions to detect cancer early, GE Healthcare today announced that it has supplied Nile Scan & Labs with its exceptional Positron Emission Tomography/ Computed Tomography (PET/CT) molecular imaging system. The new GE Discovery IQ PET/CT comes with advanced early disease detection capabilities, as well as measurements to track patients’ responses to cancer treatment.
GE’s Discovery IQ PET/CT is the company’s latest technology; it introduces certain options to help professionals lower the dose on the patient without compromising the excellent image resolution compared to previous technologies. Moreover, it has achieved high and consistent PET quantitation accuracy, which enables Nile Scan & Labs to monitor cancer activity in the body and help oncologists determine the best treatment plan after just a few sessions.
“We’re proud to partner with GE, one of the world’s leading providers of healthcare technology, to introduce this new PET/CT generation to Egypt,” stated Dr. Tarek Moharram, CEO, Nile Scan & Labs. “If we can give Egypt’s clinicians a more accurate and reliable solution to determine whether the treatment is working or not at an earlier stage, they will be able to better treat patients.”
Tamer Said, Regional Leader for GE Healthcare for North East Africa, added: “We have been working with Nile Scan & Labs for many years, they’ve installed GE’s first digital mamoraphy system in Egypt in 2000 and we are proud to continue to provide technologies that can help detect cancer early, reduce the overall mortality rate of and improve the quality of life of patients in Egypt. By providing our GE Discovery IQ PET/CT to the lab, we are further stressing our commitment to strive for a healthier Egypt, and make a positive impact in the community.”
According to the latest data available on cancer rates in Egypt, age-standardized incidence rates per 100,000 were 166.6 (both sexes), 175.9 (males), and 157.0 (females). The most common sites for cancer were liver (23.8%), breast (15.4%), and bladder (6.9%) (both sexes): liver (33.6%) and bladder (10.7%) among men, and breast (32.0%) and liver (13.5%) among women. By 2050, a 3-fold increase in incident cancer relative to 2013 was estimated1.
Nile Scan & Labs is powered by the world’s state-of-the-art technologies and Egypt’s most prominent medical professionals. With centers in Maadi, Dokki, Heliopolis, Sheikh Zayed, Downtown and Fifth Settlement, Nile Scan is dedicated to improving the level of diagnostic medical care in Egypt through GE Healthcare’s technologies, and providing quality care to its patients.
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Today, more than 14,400 GE Healthcare technologies are deployed across hospitals and clinics in Egypt. The company’s broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help customers to deliver better care to more people around the world.
http://www.genewsroom.com/press-releases/nile-scan-lab-egypt-selects-ge%E2%80%99s-latest-discovery-iq-petct-support-early-detection